At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 256 enrolled
Drug / intervention
Aliskiren +2 moredrug
Likely dose
Aliskiren 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Twenty-four Week, Open-label, Non-comparative, Multi-center Study to Assess the Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension.
In Brief
A Phase 4 clinical trial evaluating Aliskiren, Hydrochlorothiazide, and 1 other intervention for Essential Hypertension ( Mild to Moderate). Completed, enrolled 256 participants across 4 sites in 4 countries.
Detailed Summary
This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension. (defined as mean sitting Systolic Blood Pressure \[msSBP\] ≥ 140 mmHg and \< 180 mmHg and/or mean sitting Diastolic Blood Pressure \[msDBP\] ≥ 90 and \<110 mmHg).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Hungary, Romania, Slovakia
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedOct 2008
Primary CompletionAug 2009
TodayJul 2026
First PostedOct 3, 2008
Enrollment StartSep 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.7 years ago
Interventions
Aliskirendrug
Aliskiren 150 or 300 mg
Hydrochlorothiazidedrug
Hydrochlorothiazide 12.5 or 25 mg
Amlodipinedrug
Amlodipine 5 or 10 mg